Phased Innovation Awards in AIDS Vaccine Research (R21/R33)
The summary for the Phased Innovation Awards in AIDS Vaccine Research (R21/R33) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Phased Innovation Awards in AIDS Vaccine Research (R21/R33): -Purpose. This program will support prophylactic vaccine research projects that are innovative, novel, may be high risk/high impact, and that exhibit the potential to advance AIDS prophylactic vaccine design or evaluation. All areas of investigation contributing to the development of an efficacious HIV/AIDS vaccine are welcome. Clinical trials will not be supported under this initiative. -Mechanism of Support. This FOA will utilize the NIH Phased Innovation (combined R21 [Phase I, Exploratory]/R33 [Phase II, Developmental]) grant mechanism. Awards will support milestone-driven exploratory/feasibility proof of concept studies (2 year R21 phase), with possible rapid transition to expanded development (2-3 year R33 phase). Initially funded R21 studies will be tested over two years via milestone completion, and eligible R21s will be further assessed for the R33 award. -Funds Available. Funding will be based on scientific and technical merit, program priorities, and availability of funds. The R21 award will be limited to $275,000 directs over the two year award period, and the R33 award will be limited to $300,000 in direct costs per annum. NIH anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.
| Federal Grant Title: | Phased Innovation Awards in AIDS Vaccine Research (R21/R33) |
| Federal Agency Name: | National Institutes of Health |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | PA-06-519 |
| Type of Funding: | Grant |
| CFDA Numbers: | 93.85593.856 |
| CFDA Descriptions: | Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research |
| Current Application Deadline: | No deadline provided |
| Original Application Deadline: | Multiple Receipt Dates - See Link to Full Announce |
| Posted Date: | Aug 10, 2006 |
| Creation Date: | Aug 10, 2006 |
| Archive Date: | Dec 05, 2008 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses Private institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Foreign institutions are not eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. Applicants may submit more than one application, provided each application is scientifically distinct. Clinical trials or first-time-in human studies will not be supported under this FOA. (See . http://grants.nih.gov/grants/guide/notice-files/NOT-AI-05-021.html). Clinical research, including research that uses clinical specimens, is within the scope of this announcement.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster